{"entity":{"id":"impress-trial","kind":"trial","name":"IMPRESS (algenpantucel-L)","aka":[],"tldr":"The largest vaccine trial after pancreatic cancer surgery found that algenpantucel-L added nothing to standard chemotherapy.","summary":"IMPRESS enrolled 722 patients after resection of pancreatic adenocarcinoma and randomised them to standard adjuvant therapy with or without the whole-cell vaccine algenpantucel-L. Overall survival, the primary endpoint, was not improved, ending the hyperacute vaccine approach in this disease.","status":"negative","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT01072981","url":"https://clinicaltrials.gov/study/NCT01072981"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["shared-antigen-vaccine"],"targets":[],"drugs":["algenpantucel-l","gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":["vaccines-and-oncolytic-viruses"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01072981","phase":"3","setting":"Resected pancreatic cancer: adjuvant gemcitabine with or without chemoradiation, with or without algenpantucel-L","sponsor":"NewLink Genetics","result":"No overall survival benefit.","yearReported":2016,"outcomes":[]},"route":"/trials/impress-trial/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"drug":[{"id":"algenpantucel-l","kind":"drug","name":"Algenpantucel-L","route":"/drugs/algenpantucel-l/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"term":[{"id":"vaccines-and-oncolytic-viruses","kind":"term","name":"Cancer vaccines and oncolytic viruses","route":"/terms/vaccines-and-oncolytic-viruses/"}]}}